Flis Sylwia, Chojnacki Tomasz
Department of Pharmacology, National Medicines Institute, 00-725 Warsaw, Poland,
Department of Hematology, Military Institute of Medicine, 04-141 Warsaw, Poland,
Drug Des Devel Ther. 2019 Mar 8;13:825-843. doi: 10.2147/DDDT.S191303. eCollection 2019.
Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder of hematopoietic stem cells. At the molecular level, the disorder results from t(9;22)(q34;q11) reciprocal translocation between chromosomes, which leads to the formation of an oncogenic gene fusion. Instead of progress in the understanding of the molecular etiology of CML and the development of novel therapeutic strategies, clinicians still face many challenges in the effective treatment of patients. In this review, we discuss the pathways of diagnosis and treatment of patients, as well as the problems appearing in the course of disease development. We also briefly refer to several aspects regarding the current knowledge on the molecular basis of CML and new potential therapeutic targets.
慢性髓系白血病(CML)是一种造血干细胞的克隆性骨髓增殖性疾病。在分子水平上,该疾病源于染色体之间的t(9;22)(q34;q11)相互易位,这导致了致癌基因融合的形成。尽管在慢性髓系白血病分子病因的理解以及新型治疗策略的开发方面取得了进展,但临床医生在有效治疗患者方面仍面临许多挑战。在本综述中,我们讨论了患者的诊断和治疗途径,以及疾病发展过程中出现的问题。我们还简要提及了关于慢性髓系白血病分子基础的当前知识和新的潜在治疗靶点的几个方面。